The Association for Frontotemporal Degeneration
The Association for Frontotemporal Degeneration
AFTD Patient-Focused Drug Development meeting with the FDA
The FDA recognizes patients and caregivers as the true experts in chronic, lifethreatening medical conditions like FTD. People living with a condition are
uniquely positioned to inform the understanding of the therapeutic context for
drug development and evaluation. The FDA created Patient-Focused Drug
Development meetings in 2013 as a way to systematically elicit patient and
caregiver perspectives about what are the most significant symptoms that affect
patients’ lives, and how are they currently approaching treatment for their
disease.